Dow Jones 12560.20 +30.15 8:14 am PDT, April 7, 2007 NASDAQ 2471.34 +12.65 For info, visit access.smallcapnetwork.com S & P 500 1443.76 +4.39 Change your subscription status here Russell 2000 813.35 +0.00 VOLUME 07: ISSUE 37 Feature Edition: A Biotech Trading Idea Company Name: MIV Therapeutics , Inc. Stock Symbol : MIVT New Coverage Initiated: April 7, 2007 Current Price: $0.56 Average Volume: 223,438 52 Week Range: $0.35 - $1.07  Suggested Target: $1.68 Suggested Stop: $0.34 The Small Cap Network Newsletter has been on a tear recently, finding a couple of big winners that have yielded significant short-term gains. Stockgroup (OTCBB: SWEB) is up 70% since we first suggested it in late January, while Challenger Powerboats (OTCBB: CPWB) is more than 100% higher than where we saw it when it was re-recommended it in December. Well hold onto your hats - today we're as excited as ever about a biotech idea with enormous potential.... At the end of the trading day, small cap investing really isn't all that complicated - or at least it shouldn't be. The typical small cap idea we find attractive is usually just a company offering a unique service, product, or idea, but they do it far better than anyone else can. And when the product is a biotech breakthrough? Well, the potential upside may be huge.  Why all the pomp and theory? Because it's the kind of company we see when we look at MIV Therapeutics Inc. (OTCBB: MIVT).....a company with a proprietary heart stent coating technology, and more recently, a company with some validating research regarding the safety of those coated stents. In fact, this week's news (the press release is below) is about that very issue - are the coated stents fit for medical use? Early tests do indeed indicate they are. However, that's not the entire reason we're suggesting MIVT as a trading idea. No, the reason we're presenting MIV Therapeutics to our small cap enthusiasts is the company's tangible progress towards a viable product. The passage of a recent 'fatigue' test suggests to us a revenue-bearing product may be ready in the foreseeable future. If that happens, we think this stock could be catapulted, with triple-digit gains not being out of the question.  Of course, if you've ever seen a catapult in action, then you know hitching a ride once the arm starts to swing is just about impossible to do. Translation: We think the ideal time to become an MIV Therapeutics owner may be now, while it's still flying under most investors' radars.   The Unique Idea  Though our primary interest in MIV Therapeutics is in its investment value, the underlying biotechnology story is actually pretty cool.  Remember our first 'attractive small cap' criteria from above? To really get our attention, the company has to be able to do something nobody else can do, or create something nobody else can imitate. In our opinion, MIV has done that, and then some.  We've looked at the growing heart stent debate in detail before, so we're not going to belabor it here. In the interest of being thorough with our rationale though, we do have to get everyone up to speed....  A stent is just a medical device - a tube, if you will - implanted into an artery to allow blood to keep flowing. The first ones were put into use about 15 years ago, and for the most part, seemed to work. It's only been in the last few years a problem with these early stents has become significant. The older ones, which are made of bare metal, are starting to deteriorate, potentially leaving small metal fragments in a patient's bloodstream. Plus, infections around the stent started to become relatively common. More recently, stents have been coated in an effort to avoid those issues, but guess what - many of those coatings are now believed to cause scarring on the artery wall....hardly an improvement. So, a successful and safe heart stent should (1) prevent the metal mesh tube from being directly exposed to the bloodflow, and (2) also utilize a coating that doesn't result in a scarred artery wall.  Well, guess who looks like they're on the right track? You got it - MIV Therapeutics. The coating, called Hydroxyapatite (or 'HAp', for short), is very similar to the matter bones and teeth consist of. Needless to say, the 'native' nature of the coating means MIV's stents are likely to avoid some of the major problems most other stents (and therefore, stent and coating manufacturers) are now experiencing.  Better still, MIV's unique HAp technology can stay unique for a while - they own the patent. Or to be more direct, MIV's investors could enjoy many years worth of protected profits, thanks to the exclusive manufacturing and marketing rights granted to the company in 2001. Bottom line - MIV Therapeutics satisfies our 'unique' criteria.    Turning Theory Into Reality  Our second criteria is 'deliver-ability'.....can MIV actually create an acceptable stent? Well, so far, it seems like they will indeed be able to. To use a hiking metaphor, MIV appears to be closer to the end of the trail than the beginning.  The proprietary coating was already impressive, but per the recent news, the coating has been applied to a real stent. In fact, those stents appear to have met and even exceeded the FDA's requirements on stent durability (the standard is 10 years worth of reliability without mechanical failure). A third-party just performed such a longevity test, and found no failures at all in the HAp-coated stents. In other words, MIV's stents passed the test.  But here's what we think is the exciting part - the kind of stuff we have to rationalize as investors......  As you'll read more about in the press release below, it isn't the coating that was tested again....it was a complete coated stent. The manufacturer of the stent was Biosync Scientific - an India-based stent manufacturer recently acquired by, you guessed it -MIV Therapeutics.  Now, this isn't exactly a newsflash to us, or anyone for that matter. Acquiring a high-quality manufacturer was just part of the coating's natural progress towards marketability. But, think about where this stage is likely to be in the grand scheme of things. They have the patent, they have a manufacturer, they've at least satisfied the first FDA requirement, and best of all, we can't find any other stent/coating technology that appears quite as safe and effective. From where we sit, we see a light at the end of the tunnel.   If Opportunity Knocks, Answer The Door Are you thinking what we're thinking? It seems to us things are really coming together now for the company. Ergo, things may also be shaping up for shareholders. In fact, we feel so strongly about it, we're going to go ahead and suggest aggressive investors actually become MIVT share owners, while the 'ground floor' opportunity is still closer to the floor than it is to the ceiling. We're giving MIVT a target of $1.65 - a full 200% above this week's closing level of 56 cents, and close to where shares peaked in late 2005. A stop of 34 cents looks right to us, mirroring November's lows.  Aggressive? In the short-term, perhaps a little, but think about this....the 2007 heart stent market is estimated to be worth close to $7 billion, and the annual figure has been getting bigger by $1 billion each year for the last several years. Now, top that off with the recent wave of concerns (and numerous lawsuits) associated with previous-generation coated stents. If anything, most other stent and coating technology appears to be more of a liability than an asset. Though a handful of manufacturers like MIV are working on next-generation solutions, by and large, the competition within the stent market looks to us like it's actually thinning out.  So, let's say a successfully-approved MIV heart stent can capture just 5% of that potential $7 billion market (conservative, in our opinion). That would mean annual sales of about $350 million to be spread out over just 73 million I&O shares, or per-share revenue of about $5.00. Yet, the current trading level is only 56 cents per share?!?! With most price/sales ratios somewhere around 3.0, based on our hypothetical market penetration you could actually justify a valuation of at least $10.00, if not more. But, we'll stick with a more modest expectation...for now.  Ever heard the phrase 'A big fish in a little pond'? We have to wonder if it's applicable to MIV Therapeutics' situation, though a $7 billion pond is far from 'little', particularly when there seems to be fewer and fewer fish competing for billions of dollars worth of stent sales. Maybe we should describe MIV as 'A growing fish in a big pond'. Either way, we think today's MIVT owners could be pleasantly rewarded in the coming months.    MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines  Bench Test Merged Biosync Stent Platform with Company's Biocompatible Coating, Further Validating Milestone Acquisition of India-Based Subsidiary  ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that a recent Company sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the Company's polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.  The milestone bench test further validates the recent acquisition of India-based Biosync Scientific. The acquisition is expected to accelerate the commercialization of MIVT's proprietary next generation stent technology that targets an estimated $8 billion marketplace.  "We want to establish a high bench mark against which similar coating will have to be compared," said Mark Landy, President of MIV Therapeutics. "This test was a major validation of both our next generation drug eluting technology as well as our strategic move to acquire Biosync Scientific. It also reflects our mission to do everything possible in our commitment to bring to the market a safe, effective product, even if it means going beyond FDA mandates."  The rigorous bench test combined Biosync's GenX Cr-Co, a highly competitive bare metal stent platform that has already received CE Mark certification, with MIVT's HAp technology, a novel polymer-free drug-eluting stent coating. The test results proved that MIVT's microporous ceramic coating demonstrated exceptional durability with no failures, exceeding critical FDA longevity requirements.  The bench test successfully demonstrated the integrity of MIV's HAp and bare metal stents under mechanical fatigue failures for a minimum of 10 years post-implantation. There were no failures of stent structure detected at Medical Device Testing Services during 30x endoscopic inspection of either the GenX Cr-Co Hydroxyapapatite coated stents, or the GenX Cr-Co bare metal stents.  The Biosync Scientific acquisition was the latest step in MIVT's strategic plan to become a world leader in the multibillion billion dollar interventional cardiology market. MIVT also recently signed an agreement to acquire Vascore Medical, a China-based manufacturer and distributor of advanced interventional cardiology devices.  About MIV Therapeutics Inc.  MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage.  For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.  Forward-Looking Statements  Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.  Contacts  MIV Therapeutics Inc.  Investor Relations, 604-301-9545, x14  Toll-free: 800-221-5108  Fax: 604-301-9546  investor@mivtherapeutics.com  http://www.mivtherapeutics.com/ or  Trilogy Capital Partners  Financial Communications  Ryon Harms, Toll-free: 800-592-6067  ryon@trilogy-capital.com    We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  From March of 2005 through July of 2006, TGR Group LLC was paid a fee of $40,000 by MIV Therapeutics for coverage of the company. In addition, TGR Group LLC was also awarded 272,000 warrants with an exercise price of $.26 by Trilogy Capital Partners for coverage of MIV Therapeutics. All of the aforementioned warrants have been exercised and shares have been sold in the open market. On April 3rd of 2007, MIV Therapeutics renewed coverage and paid TGR Group, LLC $30,000 in cash and 100,000 warrants, convertible into restricted shares at $.50. In addition, TGR Group has been awarded 190,000 warrants, convertible at $.50 into free trading shares, by Trilogy Capital Partners for coverage of the company.  On January 19th, 2007 TGR Group LLC entered into an agreement with Stock Group Media, Inc. (a wholly-owned subsidiary of Stock Group Information Systems, Inc.) whereby Stock Group Media, Inc. will provide $50,000 worth of advertising and marketing services to TGR Group, LLC in exchange for coverage of Stock Group Information Systems, Inc. on the Small Cap Network web site and newsletter.  TGR Group LLC has been paid a fee of $25,000 cash and 500,000 shares of newly issued restricted stock directly by Challenger Powerboats for coverage. The aforementioned shares have become free trading under SEC Rule 144. On March 7, 2006, TGR Group LLC entered into a contract extension whereby TGR could receive as much as $65,000 cash and 1 million, newly issued restricted shares over the next one year period from Challenger Powerboats for coverage of the company. To date, TGR has received an additional $35,000 and 500,000 newly issued restricted shares.  From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.